CN-121971492-A - Application of akaman mucin in preparation of medicine for treating hepatocellular carcinoma

Abstract

The invention discloses an application of mucin-philin Acremonium in preparing a medicament for treating hepatocellular carcinoma, and belongs to the technical field of biological medicines. The invention discovers Akk that the growth of tumors of mice with tumors of liver cancer H22 tumor can be inhibited by improving the variety of intestinal canal species, improving the level of lactobacillus in the intestinal canal of the mice, protecting the epithelial integrity of colon cells of the mice, promoting the secretion function of colon cells, activating spleen immune response, up-regulating the level of cytokines IL-6 and IFN-gamma, and the like. Akk does not directly inhibit proliferation of liver cancer cells, but indirectly inhibits proliferation of liver cancer cells by regulating macrophages.

Inventors

• ZHOU YALI
• HUANG HAITAO
• Tang Wangjie
• Liu Nanxiu
• YAN JIANGUO
• HE YULIN
• HE YI

Assignees

• 桂林医科大学

Dates

Publication Date

20260505

Application Date

20260402

Claims (10)

1. 1. Application of akkermansia muciniphila in preparing medicaments for treating hepatocellular carcinoma.
2. 2. The use according to claim 1, wherein the medicament achieves treatment of hepatocellular carcinoma by inhibiting liver cancer tumor growth, promoting tumor tissue necrosis.
3. 3. The use according to claim 1, wherein the medicament achieves treatment of hepatocellular carcinoma by modulating intestinal flora structure, increasing intestinal flora diversity, increasing beneficial bacteria abundance.
4. 4. Use according to claim 3, wherein the beneficial bacteria comprise lactobacillus.
5. 5. The use according to claim 1, wherein the medicament is for the treatment of hepatocellular carcinoma by activating an immune response of the body and up-regulating the level of immune-related factors.
6. 6. The use according to claim 5, wherein the immune-related factors include IL-6 and IFN- γ.
7. 7. The use according to claim 1, wherein the medicament achieves an adjunctive therapeutic effect on hepatocellular carcinoma by protecting colonic epithelial integrity and promoting colonic mucosal secretion.
8. 8. The use according to claim 1, wherein said akkermansia muciniphila indirectly inhibits liver cancer cell proliferation by modulating macrophages.
9. 9. The use according to claim 1, wherein the medicament is an oral formulation in which the amount of akkermansia muciniphila administered is 10 9 cfu/time.
10. 10. A pharmaceutical composition for treating hepatocellular carcinoma is characterized by comprising an active ingredient and pharmaceutically acceptable auxiliary materials, wherein the active ingredient is one or more of Acremonium muciniphilum, bacterial suspension thereof or culture supernatant thereof.

Description

Application of akaman mucin in preparation of medicine for treating hepatocellular carcinoma Technical Field The invention relates to the technical field of biological medicines, in particular to application of akkermansia muciniphila in preparation of a medicine for treating hepatocellular carcinoma. Background Hepatocellular carcinoma (Hepatocellular carcinoma, HCC) is one of the most common malignant tumors worldwide, with more than 90 tens of thousands of new diagnoses per year and about 83 tens of thousands of deaths. The existing liver cancer has high malignancy degree and poor prognosis, and the treatment effect of surgical treatment, chemotherapy and radiotherapy on the disease is poor, and the multi-target drug sorafenib can prolong the survival time of patients, but is also very limited. Thus, the search for new treatments is an important and difficult task for current researchers and doctors, and it is urgent to search for new treatments. Disclosure of Invention The invention aims to provide an application of akkermansia muciniphila in preparing a medicament for treating hepatocellular carcinoma, so as to solve the problems in the prior art. In order to achieve the above object, the present invention provides the following solutions: according to one of the technical schemes, the application of the akkermansia muciniphila in preparing medicaments for treating hepatocellular carcinoma is provided. The second technical scheme of the invention is that the pharmaceutical composition for treating hepatocellular carcinoma comprises an active ingredient and pharmaceutically acceptable auxiliary materials, wherein the active ingredient is one or more of Achroman muciniphila, bacterial suspension thereof or culture supernatant thereof. Based on the technical scheme, the invention has the following technical effects: The invention firstly researches the relation between Akk and liver cancer cell growth and preliminarily explores the action mechanism of Akk. By integrating bioinformatics analysis, animal experiments and cell experiments, the action of Akk on liver cancer cell proliferation and the action mechanism thereof are discussed. The research results show that: (1) Akk have shown potential as biomarkers for intestinal, neurological and liver related diseases. Compared with healthy people, akk has significantly reduced abundance in patients with liver diseases such as hepatitis B virus carrying, liver cirrhosis, non-alcoholic liver disease and the like. (2) Akk can improve the intestinal canal species diversity, improve the intestinal lactobacillus level of mice, protect the colon cell epithelial integrity of mice, promote the secretion function of colon cells, activate spleen immune response, up-regulate cytokines IL-6 and IFN-gamma level and other approaches, and inhibit the growth of tumors of mice with tumors of liver cancer H22. (3) Akk does not directly inhibit proliferation of liver cancer cells, but indirectly inhibits proliferation of liver cancer cells by regulating macrophages. Drawings FIG. 1 shows Akk growth characteristics. Wherein, (A) Akk gram stain (1000X), (B) Akk formed individual colonies on BHI solid plates, and (C) Akk growth curve on BHI liquid medium. FIG. 2 shows that antibiotic treatment promotes tumor growth in H22 tumor-bearing mice of liver cancer. Wherein, (A) H22 cells are injected into BALB/C mice, broad-spectrum antibiotics are added into drinking water of the mice when an antibiotic treatment group changes water each time, an equal volume of PBS solution is added until the experiment is finished in a PBS treatment group, tumors are photographed, (B) a tumor growth curve graph is recorded every 1 day after 6 days, (C) the tumor weight of the BALB/C tumor-bearing mice, (D-E) the spleen index and the weight histogram of the BALB/C mice, and (F) the spleens of the PBS treatment group and the PSA treatment group are photographed. PBS, phosphate buffer control group, PSA, antibiotic treatment group. FIG. 3 shows Akk inhibition of tumor growth in hepatoma H22 tumor-bearing mice. Wherein, (A) H22 cells are injected into BALB/C mice, akk or E.coli is used for lavage every 1 day, the amount of the lavage bacteria is 10 9 cfu per 200 mu L, PBS group is used for lavage liquid with equal volume, tumor is photographed, (B) tumor growth curve graph is recorded every 1 day after 6 days, (C) BALB/C tumor weight of tumor-bearing mice, (D) and (E) IL-6 and IFN-gamma levels of different treatment groups are obtained. PBS, phosphate buffer control group, akk, achroman mucin-treated group, E.coli, escherichia coli-treated group. FIG. 4 shows the effect of different treatments on intestinal flora diversity and structure in tumor-bearing mice. Wherein, (A-D) alpha diversity index analysis and (E-H) principal component analysis. PBS, phosphate buffer treatment group, akk, achroman mucin treatment group, PSA, antibiotic treatment group. FIG. 5 is the effect of different treatments on the diffe